{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"One-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution.","groups":[{"description":"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.\n\nRADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16.\n\npaclitaxel: Given IV\n\ncarboplatin: Given IV\n\nexternal beam radiation therapy: Undergo external beam radiation therapy\n\nbrachytherapy: Undergo HDR brachytherapy\n\nintensity-modulated radiation therapy: Undergo IMRT\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Paclitaxel, Carboplatin, Radiotherapy)"}],"populationDescription":"Recurrence-free survival data was not collected/aggregated and therefore not analyzed.","reportingStatus":"POSTED","timeFrame":"Date of entry to date of reappearance of disease, assessed at 1 year","title":"Recurrence-free Survival","type":"PRIMARY"}